The FINANCIAL -- Berlin, September 13, 2011 – Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals today announced that results from clinical trials evaluating the use of Nexavar® (sorafenib) tablets will be presented at the 2011 European Multidisciplinary Cancer Congress (ECCO-ESMO), September 23-27, 2011, in Stockholm, Sweden.
“Through our research and development and clinical trial programs, Bayer and Onyx have established a key role for Nexavar in the treatment of advanced kidney cancer and unresectable liver cancer,” said Dr. Dimitris Voliotis, Vice President, Global Clinical Development Oncology, Bayer HealthCare. “With data evaluating Nexavar in a variety of treatment settings and patient populations being presented at ECCO-ESMO, the companies continue to demonstrate our commitment to further evaluating Nexavar to determine its safety and efficacy in multiple of tumor types.”
Related Stories
